111P - Deltex-1 single nucleotide polymorphism rs1732786A>G is associated with the prognosis of surgically resected non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-Small Cell Lung Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jang Hyuck Lee
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors J.H. Lee1, S. Kyung Min2, J.E. Choi3, M.J. Hong3, S.K. Do4, J.Y. Park5
  • 1Departments Of Biochemistry And Cell Biology, Kyungpook National University School of Medicine, 700-422 - Daegu/KR
  • 2Radiology, Kyungpook National University School of Medicine, Daegu/KR
  • 3Cell And Matrix Research Institute, Kyungpook National University School of Medicine, Daegu/KR
  • 4Biochemistry & Cell Biology, Kyungpook National University, Daegu/KR
  • 5Department Of Internal Medicine, Kyungpook National University School of Medicine, Daegu/KR



Notch signaling pathway has been implicated in the prognosis of non-small cell lung cancer (NSCLC). This study was conducted to determine the association between single nucleotide polymorphisms (SNPs) in the Notch pathway genes and survival outcomes of surgically resected NSCLC.


252 SNPs in 28 candidate genes involved in Notch pathway genes were extracted from the SABioscience, a Quiagen company (http://www.sabiosiences.com). After quality control, 64 SNPs were analyzed in the discovery set (n = 354). A replication study was performed (n = 772). All polymorphisms were genotyped using SEQUENOM's MassARRAY® iPLEX assay according to instructions of the manufacturer. The genotype association with overall survival (OS) and disease-free survival (DFS) were analyzed.


Among the 64 SNPs analyzed in the discovery set, 8 SNPs were significantly associated with OS or DFS. Among the 9 SNPs, the association was consistently observed only for DTX1 rs1732786A>G in the validation set. In combined analysis, the rs1732786A>G was significantly associated with better OS and DFS (adjusted HR [aHR] for OS, 0.81; 95% CI, 0.68–0.95; P = 0.01; aHR for DFS, 0.82; 95% CI, 0.72–0.94; P = 0.003; under codominant model). When categorized by pathological stage, the rs1732786A>G was found to be significantly associated with late stage (adjusted HR [aHR] for OS, 0.73; 95% CI, 0.60–0.89; P = 0.002; under codominant model).


Our results suggest that the DTX1 rs1732786 A>G could be a useful marker for predicting the prognosis of patients with early stage NSCLC.

Clinical trial identification

Legal entity responsible for the study

Kyungpook National University


Ministry of Trade, Industry and Energy


All authors have declared no conflicts of interest.